



## Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

June 18, 2025

NASHVILLE, Tenn.--(BUSINESS WIRE)--Jun. 18, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition.

"We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I am looking forward to seeing Mike strengthen our engagement with the investment community, communicating our vision, performance, and history of long-term value creation for all Harrow stakeholders."

Baum continued, "On behalf of the entire Harrow Family, I want to sincerely thank Jamie for her support, leadership, professionalism, and unwavering commitment over the years. She has been a trusted partner to our leadership team and a valued voice in our communications strategy. We are thankful for her continued support during this transition and wish her all the best in her well-earned retirement."

Mike joins Harrow with over a decade of experience in biotech investor relations and communications. Most recently, he served as Sr. Director, Head of Investor Relations at Sensei Biotherapeutics, where he led the investor relations and communications function. Prior to joining Sensei, Mike was a Managing Director and a member of the leadership team at Solebury Trout, a leading biotech investor relations and strategic advisory firm. During his time there, he led the investor relations strategy and execution for several public and private biotech companies. Mike started his career on the equity sales desk at Summer Street Research Partners, an institutional equity research and trading firm focused exclusively on the healthcare sector.

"I'm thrilled to join Harrow at such an exciting time in its evolution," said Mike Biega. "Harrow's commitment to delivering accessible, affordable, and differentiated ophthalmic solutions resonates deeply, and I look forward to working closely with the leadership team to strengthen investor engagement and elevate the company's story as a leading force in U.S. eyecare."

### About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit [harrow.com](https://harrow.com).

### Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at [sec.gov](https://sec.gov). Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250618606966/en/): <https://www.businesswire.com/news/home/20250618606966/en/>

Mike Biega, VP of Investor Relations and Communications  
[mbiega@harrowinc.com](mailto:mbiega@harrowinc.com)  
617-913-8890

Source: Harrow, Inc.